Wall Street brokerages expect BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to announce earnings per share (EPS) of ($0.06) for the current quarter, Zacks reports. Five analysts have provided estimates for BioDelivery Sciences International’s earnings, with the lowest EPS estimate coming in at ($0.25) and the highest estimate coming in at ($0.01). BioDelivery Sciences International posted earnings of ($0.16) per share during the same quarter last year, which would indicate a positive year over year growth rate of 62.5%. The firm is expected to announce its next quarterly earnings results on Thursday, August 8th.
On average, analysts expect that BioDelivery Sciences International will report full year earnings of ($0.14) per share for the current financial year, with EPS estimates ranging from ($0.42) to ($0.05). For the next year, analysts forecast that the company will post earnings of $0.25 per share, with EPS estimates ranging from $0.09 to $0.46. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that follow BioDelivery Sciences International.
BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings results on Monday, May 6th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.03. BioDelivery Sciences International had a negative return on equity of 43.40% and a negative net margin of 42.09%. The company had revenue of $19.77 million during the quarter, compared to the consensus estimate of $19.60 million.
BDSI has been the topic of several recent research reports. Cantor Fitzgerald set a $8.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Friday, March 22nd. Zacks Investment Research cut BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Wednesday, March 20th. BidaskClub cut BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research note on Friday, May 17th. SunTrust Banks started coverage on shares of BioDelivery Sciences International in a research report on Tuesday, March 19th. They set a “buy” rating and a $7.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of BioDelivery Sciences International in a report on Friday, March 15th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. BioDelivery Sciences International currently has a consensus rating of “Buy” and an average price target of $6.20.
Shares of BDSI stock traded down $0.05 during mid-day trading on Wednesday, reaching $4.30. The stock had a trading volume of 20,517 shares, compared to its average volume of 743,186. BioDelivery Sciences International has a one year low of $2.35 and a one year high of $5.37. The company has a current ratio of 2.88, a quick ratio of 2.57 and a debt-to-equity ratio of 1.90. The company has a 50 day moving average of $4.50. The company has a market capitalization of $392.95 million, a price-to-earnings ratio of -5.90 and a beta of 0.47.
In other news, Director Mark A. Sirgo sold 484,752 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $4.22, for a total transaction of $2,045,653.44. Following the completion of the transaction, the director now directly owns 2,559,803 shares of the company’s stock, valued at $10,802,368.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Healthcare Master Fun Broadfin sold 2,000,000 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The shares were sold at an average price of $5.00, for a total transaction of $10,000,000.00. The disclosure for this sale can be found here. Insiders sold 4,339,037 shares of company stock worth $21,313,438 in the last 90 days. Corporate insiders own 8.94% of the company’s stock.
Several large investors have recently modified their holdings of the stock. Emerald Advisers LLC lifted its position in BioDelivery Sciences International by 881.4% during the first quarter. Emerald Advisers LLC now owns 1,734,422 shares of the specialty pharmaceutical company’s stock valued at $9,192,000 after purchasing an additional 1,557,692 shares during the last quarter. Emerald Mutual Fund Advisers Trust increased its stake in BioDelivery Sciences International by 836.4% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 1,556,947 shares of the specialty pharmaceutical company’s stock worth $8,252,000 after buying an additional 1,390,682 shares during the period. Nantahala Capital Management LLC increased its position in BioDelivery Sciences International by 64.0% during the 4th quarter. Nantahala Capital Management LLC now owns 2,733,567 shares of the specialty pharmaceutical company’s stock valued at $10,114,000 after purchasing an additional 1,066,900 shares during the period. Millennium Management LLC increased its position in BioDelivery Sciences International by 703.6% during the 4th quarter. Millennium Management LLC now owns 981,422 shares of the specialty pharmaceutical company’s stock valued at $3,631,000 after purchasing an additional 859,292 shares during the period. Finally, Pura Vida Investments LLC purchased a new position in shares of BioDelivery Sciences International in the 4th quarter worth approximately $2,305,000. Hedge funds and other institutional investors own 56.73% of the company’s stock.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
See Also: Trading on Margin
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.